Resmed (RMD) Q3 FY2026 earnings: revenue $1.4 billion, up 10.8% on the year
Resmed Inc. (RMD) reported revenue of $1.4 billion for Q3 FY2026, the quarter ended 31 March 2026, up 10.8% on the same quarter a year earlier. Net income was $399 million, up 9.2% on the year, and diluted earnings per share $2.74. The figures are the company's own, from the 10-Q it filed with the SEC on 1 May 2026.
Revenue
$1.4 billion
+10.8% on the year · +0.6% on the quarter
Q4 FY2024Q3 FY2026
Operating margin
34.9%
33.0% a year earlier
Q4 FY2024Q3 FY2026
Net income
$399 million
+9.2% on the year · +1.6% on the quarter
Q4 FY2024Q3 FY2026
Diluted EPS
$2.74
+10.5% on the year · +2.2% on the quarter
Q4 FY2024Q3 FY2026
this quarterthe same quarter a year earlierHover a bar for its figure.
What management said
Revenue rose 11% to $1.43 billion: The company reported revenue of $1,431.4 million, up 11% from $1,291.7 million, or 8% on a constant currency basis, driven by demand for sleep devices, masks and accessories.
Operating income up 17%, EPS up 10%: GAAP income from operations rose 17% to $499.8 million. GAAP diluted EPS was $2.74, up 10%. Non-GAAP diluted EPS was $2.86, up 21%, against $2.37 a year earlier.
Masks and other grew faster than devices: Devices revenue was $735.7 million, up 9% (6% constant currency). Masks and other revenue was $524.8 million, up 15% (12% constant currency).
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
Q3 FY2026
Q2 FY2026
Q3 FY2025
On the quarter
On the year
Last 8 quarters
Operating cash flow
554
340
579
+63.1%
-4.2%
Capital expenditure
33.7
28.5
20.8
+17.9%
+61.8%
Free cash flow
520
311
558
+67.2%
-6.7%
Free cash flow margin
36.4%
21.9%
43.2%
Cash from investing
-58.0
-50.9
-31.8
Cash from financing
-255
-258
-144
Depreciation and amortisation
59.0
49.9
43.7
+18.2%
+35.0%
Share-based compensation
26.8
28.9
24.1
-7.4%
+11.1%
Buybacks
175
175
75.0
-0.0%
+133.3%
Dividends paid
87.2
87.6
77.7
-0.4%
+12.3%
Dividend per share
$0.60
$0.60
$0.53
0.0%
+13.2%
Diluted shares, weighted
146m
146m
147m
-0.4%
-1.0%
Shares outstanding at period end
145m
146m
147m
-0.4%
-1.1%
Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.
Balance sheet
$ million
Q3 FY2026
Q2 FY2026
Q3 FY2025
On the quarter
On the year
Last 8 quarters
Shareholders' equity
6,492
6,321
5,546
+2.7%
+17.1%
Debt
664
664
673
+0.0%
-1.3%
Operating lease liabilities
150
154
138
-2.8%
+8.6%
Other liabilities
1,478
1,365
1,210
+8.3%
+22.2%
Total liabilities and equity
8,784
8,503
7,567
+3.3%
+16.1%
Fixed assets
567
564
535
+0.5%
+5.9%
Goodwill
3,043
3,044
2,849
-0.0%
+6.8%
Intangible assets
425
430
430
-1.2%
-1.1%
Cash and equivalents
1,661
1,417
933
+17.2%
+78.0%
Receivables
999
986
908
+1.3%
+10.0%
Inventory
912
922
863
-1.1%
+5.7%
Other assets
1,178
1,140
1,049
+3.3%
+12.2%
Total assets
8,784
8,503
7,567
+3.3%
+16.1%
Questions
What was Resmed's revenue in Q3 FY2026?
Resmed (RMD) reported revenue of $1.4 billion for Q3 FY2026, the quarter ended 31 March 2026, up 10.8% on the same quarter a year earlier.
How much did Resmed earn in Q3 FY2026?
Net income for Q3 FY2026 was $399 million, up 9.2% on the year, and diluted earnings per share $2.74.
When did Resmed report Q3 FY2026 results?
Resmed filed its 10-Q for the quarter ended 31 March 2026 with the SEC on 1 May 2026.
Each quarter as filed, linked to its filing. Read more* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. A quarter marked † is shown as the company last restated it in a later filing, so it compares with the quarters around it on one basis; rest on a figure for the one first filed. EPS is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.
10-Q for the period ended 31 March 2026, filed 1 May 2026: the filing.